Enthera initiates clinical trial for bowel disease and T1D

Biotech company Enthera Pharmaceuticals has started a clinical trial to evaluate its product, Ent001, is safe and tolerated. This will lay the groundwork for the evaluation of the use of Ent001 in patients with inflammatory bowel disease and Type 1 diabetes. Ent001 is an antibody designed to target the pathway which plays a critical role in inflammatory bowel disease (IBD) and Type 1 diabetes (T1D), since Ent001 is designed to prevent cell death and inflammation underlying these diseases.

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).